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The mechanism by which T cells and cytokines regulate 
immune processes in skin can be investigated by studying 
patients with leprosy. The disease, caused by the obligate 
intracellular bacterium Mycobacterium leprae, forms a spec-
trum. At one pole, patients with tuberculoid leprosy are able 
to restrict the growth of the pathogen and their skin lesions 
are characterized by a predominance of CD4+ T cells and 
type 1 cytokines including interleukin 2 and interferon y. At 
the opposite pole, patients with lepromatous leprosy are un-
Leprosy, or Hansen's Disease, is a chronic, infectious disease of 
human beings that primarily affects the skin, mucous membranes, 
and nerves. The disease is caused by a rod-shaped bacillus, Mycobacter-
ium /eprae. The leprosy bacillus was identified in 1874 by the Norwe-
gian physician Gerhard Henrik Armauer Hansen (1841-1912). 
In both the Old and New Testaments the name leprosy is given to a 
number of physical conditions unrelated to leprosy. These conditions 
were considered a punishment from God for sin. The victim was said 
to be in a state of tsara'ath, or defilement. This Hebrew term was later 
trans lated as lepros, from which came the word leprosy.· 
T his excerpt, recently published on CD-ROM, sug-gests that the earliest case reports ofleprosy were mis-diagnosed. Nevertheless, in the current era, sufferers of leprosy are some of the most stigmatized individu-als in society. Although Hansen discovered the lep-
rosy bacillus 120 years ago, the pathogen evades attempts at culture 
and has recently become resistant to some antibiotic therapy. These 
are clearly reasons enough to study leprosy. But an equally compel-
ling reason is that leprosy provides an extraordinary window onto 
immune regulation in humans. 
Leprosy is an ideal model because it presents as a spectrum of 
clinical manifestations that correlate with immune responses to the 
pathogen [1] (Fig 1A). At one end of the spectrum, patients with 
tuberculoid leprosy typify the resistant response that restricts the 
growth of the pathogen. The number of lesions is few, although 
tissue and nerve damage is frequent. At the opposite end of this 
spectrum, patients with lepromatous leprosy represent extreme sus-
ceptibility to Mycobacterium [eprae infection. In lepromatous leprosy, 
the skin lesions are numerous and growth of the pathogen is un-
abated, resulting in many viable M. [eprae throughout the skin le-
sions. These clinical presentations correlate with the level of cell-
mediated immunity (CMI) against M. [eprae. The standard measure 
of CMI to the pathogen is the Mitsuda reaction. Patients are chal-
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able to contain the infection and their skin lesions are charac-
terized by a predominance of CD8+ T cells and type 2 cyto-
kines including interleukins 4 and 10. A key determinant of 
the T-cell cytokine response may be interleukin 12, which 
selectively favors expansion of CD4+ T cells producing in-
terferon y. By understanding the factors that regulate 
T-cell and cytokine responses in leprosy, it should be possible 
to devise specific immunologic interventions in diseases of 
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lenged by intradermal injection of M. [eproe and induration is mea-
sured 3 weeks later. The test is positive in tuberculoid patients and 
negative in lepromatous patients. 
It is widely agreed that T cells involved in cell-mediated immu-
nity are pivotal in determining the outcome of infection with M. 
[eprae, because skin test and lymphocyte reactivity are positive in 
tuberculoid patients but negative in lepromatous patients. Yet there 
is an interesting paradox in that CMI and humoral responses exhibit 
an inverse relationship. Anti - M. leprae antibodies are most elevated 
in patients with the lepromatous form of the disease, and therefore 
are not thought to playa role in protection. A goal of our studies was 
to determine whether the resistance to M. [eprae infection (asso-
ciated with CMI) versus the susceptibility to M. [eprae infection 
(associated with humoral responses) could be correlated with dis-
tinct cytokine patterns. 
THE TH1-TH2 PARADIGM 
A major paradigm shift in how we think about immunoregulation 
resulted from the analysis of cytokine patterns produced by murine 
CD4+ T-cell clones [2]. T cells that produce interleukin 2 (IL-2) 
and interferon y (IFN-y), termed Th 1 cells, could be envisioned as 
contributing to CMI, whereas T cells that produce IL-4 and IL-5, 
termed Th2 cells, augment humoral responses. In murine models of 
intracellular infection, resistant versus susceptible immune re-
sponses appear to be regulated by these two T-cell sub populations 
[3 - 5]. Th 1 cells preferentially activate macrophages to kill or in-
hibit the growth of the pathogen, resulting in mild or self-curing 
disease. In contrast, Th2 cells facilitate humoral responses and in-
hibit some cell-mediated immune responses, resulting in progres-
sive infection. Through the investigation of the active lesions of 
leprosy, we have found that this paradigm may explain the dichot-
omy of responses to many human pathogens (Fig 2) . 
CYTOKINE PATTERNS IN LEPROSY LESIONS 
Initially, IL-2 was detected in leprosy lesions by monoclonal anti-
bodies and immunoperoxidase techniques [6,7]. All order of magni-
tude greater number of IL-2-containing cells were present in tu-
berculoid lesions as compared with lepromatous lesions. By in situ 
hybridization, it became readily apparent that IFN-y mRNA was 
also more strongly expressed in tuberculoid lesions [8]. These early 
studies indicated that the "Th 1 " cytokines were most prominent in 
the form of leprosy that is characterized by CMI to the pathogen . 
To more fully probe patterns of cytokines in lesions at the ex-
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Figure 1. The spectrum of leprosy. 
tremes of the spectrum of leprosy, we exploited the power of 
polymerase chain reaction (PCR) to analyze the local cytokine pat-
tern [9,10). The followed strategy was devised: 1) RNA was ex-
tracted from biopsy specimens; 2) polyadenylated mRNAs were 
reverse transcribed to obtain cytokine cDNAs; and 3) those cDNAs 
were detected with high sensitivity by PCR using cytokine specific 
primers. The discriminatory capacity of the PCR results was en-
harlCed by normalizing the PCR comparisons to specific CD30-
chain mRNA found only in T cells. 
The striking observation was that clear differences in cytokine 
peR profiles were observed between tuberculoid and lepromatous 
lesions, and those differences were consistent across lesions of all 
patients: IL-2 and IFN-y mRNAs were markedly higher in tubercu-
loid lesions, whereas IL-4, IL-5, and IL-10 mRNAs were character-
istic of lepromatous lesions (Fig 1B). The cytokine patterns that 
were detected in the leprosy lesions are remarkably similar to the 
Th 1 and Th2 patterns of murine CD4+ cells. Th 1-like cytokine 
mRNAs were abundant in tuberculoid lesions, which are basically 
self-healing and characterized by resistance to growth of M. leprae. 
In marked contrast, Th2-like cytokine mRNAs were abundant in 
lepromatous lesions, correlating with immunologic unresponsive-
ness to M. leprae. Similar functional populations of human T cells 
were initially described in several experimental systems, including 
T-cell response to different antigens [11-13), and in diseases in-
cluding atopy [14) and Loa loa infection [15,16). Nevertheless, in-
vestigation of leprosy permitted the delineation of comparable 
human Th 1 and Th2 responses in response to a sillgle pathogen, 
which correlate with the clinical course of the infection. 
The abundance ofIL-2 and IFN-y in tuberculoid lesions is likely 
to contribute to the resistant state of immunity in these patients. 
IFN-y is well known to enhance production of reactive oxygen and 
nitrogen intermediates [17) by macrophages and stimulate them to 
kill or restrict the growth of mycobacteria [18,19] and other intra-
cellular pathogens [20). IFN-y also augments expression of HLA-
DR and intercellular adhesion molecule 1 (ICAM-I), which facili-
tates T -cell-accessory-cell interaction [21). IL-2 may contribute to 
the host defense by inducing the clonal expansion of immune-acti-
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vated cytokine-producing T cells and augmenting the production of 
IFN-y [22). 
In contrast to the set of cytokine mRNAs present in tuberculoid 
lesions that might be involved in CMI and inflammation, those 
found to be increased in lepromatous lesions might be expected to 
contribute to the immune unresponsiveness and failure of macro-
phage activation in these individuals. IL-4 was increased in lep-
romatous lesions compared with tuberculoid lesions. IL-4 may con-
tribute to the elevated anti-M. leprae antibodies in lepromatous 
patients via its role in differentiation and immunoglobulin class 
switching of B cells [23] as well as its abi lity to stimulate Th2 
proliferation [24). IL-4 also has a negative immunoregulatory effect 
on CMI that could lead to enhanced bacterial growth, because it 1) 
blocks IL-2 -dependent proliferation of human T cells by down-
regulation of IL-2 receptors [25]; 2) abrogates both the IFN-y-
mediated activation of monocytes and their anti-leishmania! activ-
ity [26); 3) downregulates CD14 expression on monocytes and pro-
duction of IL-IP and tumor necrosis factor a (TNF-a) [27); and 4) 
blocks macrophage nitric oxide generation necessary for killing 
intracellular pathogens [28]. 
CYTOKINE PROFILES OF CD4 AND CDS T CLONES 
What are the T-cell populations responsible for the production of 
these distinct cytokine patterns? Earlier immunoperoxidase and 
immunoflourescence studies had indicated differences in the 
CD4 : CDS ratio at the poles of the leprosy spectrum [6,7,29 - 31). 
The data from these studies indicate that in tuberculoid leprosy 
leSIOns the CD4+ population predominated, with a CD4: CDS 
ratio of 1.9: 1 '. wherea~ in the lepromatous lesions the CDS+ popu-
lation predomlIlates with a CD4 : CDS ratio of 0.6 : 1. Furthermore, 
CD4+ cells in tuberculoid lesions express the T-memory pheno-
type (CD45RO+) [32]. The majority of CDS+ cells in lepromatous 
lesions are CD2S-, indicating that they are of the T-suppressor 
phenotype [32) . Of CD4+ cells cultured directly from tuberculoid 
lesions, one in 60 react to M. leprae antigens [32]. CD8+ cells from 
lepromatous lesions fail to proliferate to antigen but can be activated 
by M. leprae to inhibit proliferative responses by CD4+ cells and are 
termed "T-suppressor cells" [33,34). 
To gain insight into the molecular and cellular basis of T -cell-
mediated protection and suppression, as well as to correlate the 
cytokine patterns in lesions with functional subsets of CD4+ ar1d 
CDS+ T-cells, we examined the profile of cytokines produced by 
T-cell clones derived from patients across the spectrum of leprosy 
(35) . The patterns of cytokine secretion of these clones were com-
pare? to the cytokine profiles of cells specific for other antigens 
beanng the. same surface phenotype, but differing in function. CD4 
clones speCific for teta~1Us toxoid ar1d CDS major histocompatibility 
complex c.lass I - restncted T -cytotoxic cells specific for HLA-B27 
were studied. The T-cell clones were stimulated via the T-cell 
receptor-CD3 complex using anti-CD3 monoclona! ar1tibodies, 
and the cytokines that they released were measured [35) . 
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All of the M. leprae-specific CD4+ clones obtained from tuber-
culoid patients produced IL-2, IFN-y, and granulocyte/macro-
phage colony-stimulating factor, but little or no IL-4 or IL-5, simi-
lar to the pattern of cytokines characteristic of murine Th 1 cells. 
These clones also lacked helper activity for antibody formation; we 
therefore designated them as "type 1" CD4+ T cells. The CD4+ 
tetanus toxoid clones produced low levels of IFN-y and IL-2, but 
high levels of IL-4 and IL-5, a pattern similar to that of Th2 cells. 
These clones were found to have B-cell helper activity and were 
designated as "type 2" CD4+ T cells. Thus, functionally different 
CD4+ T cells from strongly antigen-reactive donors can be sub-
typed into two groups, similar to the murine counterparts, based on 
cytokine patterns. 
Similarly, we were able to define subpopulations of CD8+ T cells 
based on their cytokine pattern. The majority of the CD8+ all ore-
active T-cytotoxic clones tested secreted IFN-y, but made no de-
tectable IL-4 or IL-5 . Of particular interest, the pattern of cytokine 
production by the CD8+ T -suppressor clones was characterized by 
high levels of IL-4 and low levels of IFN-y. Based on patterns of 
cytokine secretion, particularly of IL-4, the data suggest that the 
human CD8 population can also be divided into two functional 
subsets, which we designate as "type 1" and "type 2" CD8+ T cells. 
IL-4 facilitated the growth of CD8+ T cells and T cell clones 
from lepromatous donors, suggesting that it may act as an autocrine 
growth factor for the CD8+ type 2 subset [36]. The critical role for 
IL-4 in mediating suppression of CD4+ T-cell responses was 
shown using neutralizing anti - IL-4 antibodies [35]. We also found 
that the suppressor activity of CD8+ type 2 cells could be abrogated 
by the addition of anti-IL-4 antibodies to the cultures. 
It is a well known immunologic generalization that a dichotomy 
exists between antibodies to a pathogen and cell-mediated immu-
nity. As a case in point, lepromatous leprosy patients, lacking CMI, 
have significantly higher levels of anti-M. leprae antibodies than 
tuberculoid patients. These data and the results of murine infection 
models can best be reconciled by appreciating that IL-4 has the 
capacity not only to enhance antibody formation, but also to depress 
multiple components of CM! required for protection. However, it 
should be noted that there may be significant contributions to the 
outcome of infection by other cytokines. More likely it is the matrix 
of cytokines that determine the utlimate biologic response at the 
locus of infection, protective immunity , and/or immunopathology. 
A ROLE FOR IL-I0 
Although IL-I0 mRNAs were prominent in lepromatous lesions, 
the T-cell clones from the lesions produced only small amounts of 
IL-10 protein [35,36]. The presence in lepromatous lesions of IL-
10, a cytokine that can down-regulate cytokine production by CD4 
T cells in the relative absence of IFN-y or IL-2, suggests a possible 
role for this cytokine in the specific immunologic unresponsiveness 
to M. leprae antigens [37,38]. To define more precisely the role of 
IL-10 in human infection, we studied in vitro responses toM. leprae 
[36]. M. leprae triggered IL-l 0 release from peripheral blood mono-
nuclear cells of patients and healthy donors; the predominant source 
of the IL-I0 was found to be macrophages. Neutralizing anti - IL-
10 monoclonal antibodies significantly enhanced M. leprae-specific 
T-cell proliferation and release of TNF-a, granulocyte/macro-
phage colony-stimulating factor, and IFN-y. These data indicate 
that M. leprae induces IL-l 0 production, which inhibits T-cell pro-
liferation and the release of cytokines that have anti-mycobacterial 
properties. 
REVERSING CYTOKINE PATTERNS 
Leprosy is not a static disease but an extremely dynamic condition in 
which immune changes alter the clinical manifestations, in the 
form of "reactional states." These reactional states provide a win-
dow onto the dynamic immune events associated with immunore-
gulation in human disease. Reversal reactions are generally known 
to be naturally occurring delayed-type hypersensitivity (DTH) re-
sponses to M. leprae, associated with clearance of bacilli from lesions 
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and upgrading towards the tuberculoid pole [39-43] . The onset of 
reversal reactions is associated with the emergence ofT-ceil respon-
siveness to M. leprae. Reversal reaction lesions are characterized by 
the influx of CD4+ T cells [44]. W e analyzed the dynamic changes 
in cytokine patterns by studying biopsy specimens from patients 
before the onset of reversal reaction and during the reaction [10]. As 
patients with reversal reaction upgrade from the lepromatous pole, 
we found a concomitant switch from type 2 to type 1 cytokine 
production locally. These data provide clear evidence that DTH 
responses involve the influx of T cells secreting type 1 cytokines. 
Furthermore, because the cytokine pattern changes during a natu-
rally occurring reaction, it should be possible to devise immuno-
therapeutic tools to artificially reverse the cytokine profile. In fact, 
cutaneous administration of either IL-2 or IFN-y to lepromatous 
patients results in some clearance of bacilli from lesions [19,45], 
although there is little or no gain in immunologic memory. 
LEARNING FROM LEISHMANIASIS 
Leishmaniasis, like leprosy, is not a single disease entity, but a set of 
clinical entities each with a differing immunopathogenesis. These 
different clinical presentations may comprise an immunologic spec-
trum [46]. Patients with localized cutaneous leishmaniasis (LCL) 
have few skin lesions in which the growth of the parasite is re-
stricted. In contrast, patients with diffuse cutaneous leishmaniasis 
(DCL) have widely disseminated lesions and the growth of the 
parasite appears to be unabated. The Montenegro test, a DTH re-
sponse to intradermal challenge with Leishmania antigen is positive 
in LCL patients and negative in DCL patients. A minority of LCL 
patients heal, but subsequently relapse to the mucocutaneous 
(MCL) form. Patients with MCL may fall somewhere in between 
the two poles of the LCL-DCL spectrum, having some resistance 
against disseminated infection, but not being able to fully eliminate 
the parasite, a situation resulting in chronic destructive lesions. 
By PCR we determined that the type 1 cytokine pattern was 
present in the Montenegro reaction and the self-healing LCL group 
[47]. The abundance of IL-2, IFN-y, and lymphotoxin is likely to 
contribute to the resistant state of immunity and elimination of 
parasites. On the other hand, MCL lesions appear to be character-
ized by a mixture of type 1 and type 2 cytokines. The greatest 
difference found in MCL versus LCL lesions was the several orders 
of magnitude greater amount of IL-4 mRNA in MCL lesions [48]. 
Although IFN-y is present, the levels of IL-4 may be sufficient to 
inhibit macrophage function so that all the parasites are not elimi-
nated and the infection persists. In DCL lesions, the level ofIL-4 is 
greatest, so that the parasite's growth is unabated. These data indi-
cate the crucial role of IL-4 in determining outcome in cutaneous 
leishmaniasis. Furthermore, these studies provide evidence that the 
pathogenesis of human leishmaniasis is associated with distinct cy-
to kine patterns that conform to the Th 1-Th2 paradigm. 
To gain insight into the functional role of the CD4+ and CD8+ 
subsets in LCL lesions in contributing to the observed cytokine 
patterns, we examined the cytokine mRNAs of the sorted popula-
tions from lesions [49]. The CD4+ subset was characterized by high 
levels of IFN-y and lymphotoxin mRNAs, thereby conforming to 
the type 1 cytokine pattern. In contrast, the CD8+ subset was char-
acterized by high levels of IL-4 mRNAs with weak expression of 
IFN-y and lymphotoxin RNAs, consistent with a type 2 cytokine 
pattern. Finally, IL-10 mRNA was present in both subsets but more 
strongly expressed in the CD8+ subset. The outcome of the human 
immune response to leishmania, in a manner analogous to myco-
bacteria, may depend on the balance between CD4+ type 1 T cells 
and CD8+ type 2 T cells. 
FACTORS THAT INFLUENCE THE CYTOKINE PATTERN 
One of the major issues in immunology today is the elucidation of 
the key factors that determine or bias Th 1 versus Th2 responses. In 
the murine model of leishmaniasis, distinct antigen fractions of 
Leishmania, as well as antigen dose, select the functional T-cell 
population [50] . Yet more current data in a mouse model indicates 
VOL. 102. NO.6 JUNE 1994 
that identical T-cell receptors, hence identical antigens, can give 
rise to the Th 1 versus Th2 patterns [51]. Our studies of human 
leishmaniasis indicate that the human T-cell populations responsi-
ble for the Th 1 and Th2 patterns bear distinct T-cell receptors and 
hence may recognize distinct antigens [49]. 
In mouse models, the antigen-presenting cell may be a determin-
ing factor. Macrophages may preferentially present antigen to Th 1 
cells , but B-cells present antigen to Th2 cells [52]. It is noteworthy 
that Langerhans cells, powerful antigen-presenting cells of the skin, 
can present to both Thl and Th2 cells, but when ultraviolet irra-
diated present only to Th2 cells [53]. Cytokine patterns may be 
specific according to anatomic location: T cells in lymphoid org~ns 
draining nonmucosal tissue sites produce IL-2 whereas those dram-
ing mucosal sites produce IL-4 [54]. It is also important to consider 
the major histocompatibility complex genotype that may select par-
ticular T-cell populations [55]. In leprosy, the major histocompati-
bility complex restricting element may be critical: the majority of 
CD4 type 1 cells are restricted by HLA-DR [56] , but the CDS 
T -suppressor type 2 cells are restricted by HLA-DQ [57] . 
Many immunologists consider that "natural immunity" is in-
volved in determining outcome in that cells other than T cells may 
rapidly produce cytokines that bias the T-cell cytokine response 
[58] . Infected macrophages usually release IFN-a and IL-12, which 
activate natural killer cells to release lFN-y, with a subsequent bias 
towards a Th 1 response [59]. In vivo, susceptible mice are cured of 
L. major infection when recombinant IL-2 is administered before or 
at the time of infection [60,61]. 
IL-12: A KEY DETERMINANT? 
We investigated the role ofIL-12 in regulating type 1 T-cell re-
sponses in human infection by employing leprosy as a model [62] . 
The local production ofIL-12 in leprosy lesions was evaluated using 
the polymerase chain reaction. IL-12 is a 70-kD heterodimer 
produced by macrophages. The constitutively produced IL-12 
p35 mRNA was present at equivalent levels in both forms of the 
disease. In contrast, IL-12 p40 mRNA levels were significantly 
higher in tuberculoid than lepromatous lesions. Therefore, the local 
expression of IL-l2 was greatest in the group of patients character-
ized by type 1 cytokine responses. 
One characteristic of IL-12 is its potent T-cell growth factor 
activity [63]. We found that T-cell proliferation to M. leprae was 
dependent on the endogenous production of IL-12 in that we could 
block proliferation in vitro by the addition of neutralizing IL-12 
antibodies. IL-12 has been shown to direct T cells in a primary 
response towards a type 1 cytokine pattern [64-66]. A striking 
finding of our analysis ofT-cell res"ponses in leprosy was that rIL-12 
induced proliferation of CD4+ type 1 cell clones from tuberculoid 
lesions but not CDS+ type 2 cell clones from lepromatous lesions. 
All clones proliferated in response to rIL-2. Therefore, a mechanism 
by which IL-12 may contribute to CMl is via the preferential ex-
pansion of differentiated T cells committed to the type 1 cytokine 
pattern. 
Can IL-2 be used as an immunotherapeutic adjuvant to reverse 
T-cell unresponsiveness and induce type 1 cytokine responses? 
Towards this goal, we explored whether rlL-12 could potentiate 
antigen-induced T-cell responses and augment CMl in unrespon-
sive lepromatous patients. We observed an IL-12-dependent en-
hancement ofT-cell responses in lepromatous patients that could be 
attributed to an increase in CD4+ T cells. Furthermore, IL-12 in-
duced a preferential increase in the capacity ofT cells to produce the 
type 1 cytokine, IFN-y, versus the type 2 cytokine, IL-4. Perhaps 
more intriguing was the ability of anti-IL-10 to augment rIL-12 
plus M. leprae-stimulated T-cell proliferation in some patients to 
levels approaching those of tuberculoid patients. It should be noted 
that T-cell responses and IFN -y production could not be augmented 
in all lepromatous patients. Therefore, additional factors may be 
responsible for inducing T-cell responsiveness and type 1 cytokine 
responses to infectious pathogens. Yet our data and studies of 
human immunodeficiency virus infection [67] indicate the potential 
usefulness as IL-12 in the immunotherapy of infectious disease. 
Thl-Th2 PARADIGM 831 
Perhaps combination immunotherapy, employing antagonists to 
"negative" regulatory cytokines, would be a more effective strategy 
in combating human infectious disease [66,6S]. Hopefully, such 
approaches can help patients with leprosy and other devastating 
diseases. 
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